close

Fundraisings and IPOs

Date: 2017-02-21

Type of information: Private placement

Company: Auris Medical (Switzerland)

Investors:

Amount: $9.1 million

Funding type: private placement

Planned used: Auris Medical intends to use the net proceeds from the offering for working capital and general corporate purposes.

Others:

  • • On February 21, 2017, Auris Medical announced the closing of its previously announced public offering of 10,000,000 common shares and 10,000,000 warrants, each warrant entitling its holder to purchase 0.70 of a common share. The warrants are exercisable for five years. Net proceeds to the Company from the sale of the units were approximately $9.1 million.
  • The company also announced the closing of the sale of an additional 1,350,000 warrants pursuant to the underwriter's partial exercise of its 30-day option to purchase up to 1,500,000 additional common shares and/or 1,500,000 additional warrants at the public offering price less underwriting discounts.
  • • On February 15, 2017, Auris Medical announced the pricing of its public offering of 10,000,000 common shares and 10,000,000 warrants, each warrant entitling its holder to purchase 0.70 of a common share. The common shares and warrants are being sold in units comprised of one common share and one warrant at the public offering price of $1.00 per unit. The anticipated gross proceeds amount to $10 million. The warrants will be immediately exercisable at a price of $1.20 per common share and are exercisable for five years.
  • • On February 14, 2017,  Auris Medical announced that it is offering to sell common shares and warrants to purchase its common shares in an underwritten public offering pursuant to an effective registration statement on Form F-3 filed with the Securities and Exchange Commission (SEC). The common shares and warrants are being sold in units. In connection with this offering, the Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the common shares and/or warrants sold in the offering. All of the common shares and warrants are being offered by the Company.
  • Roth Capital Partners, LLC is acting as sole book-running manager for the proposed offering.
 

Therapeutic area: Otorhinolaryngology

Is general: Yes